XSpray Pharma AB
Research XSpray Pharma AB (XSPRAY) on Bullrun: market cap SEK 767.20M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXSPRAY
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 767.20M
- Financial periodQ1 2026
- Net income-SEK 35.36M
- Free cash flow-SEK 31.74M
Valuation Snapshot
latest market cap is SEK 767.20M.
About XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the treatment of kidney cancer;
Frequently asked questions
What is XSpray Pharma AB's market cap?
XSpray Pharma AB's market capitalization is SEK 767.20M.
What does XSpray Pharma AB do?
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia;